Risk of Hepatitis B Reactivation in Patients Receiving Ibrutinib: The National Veterans Affairs Cohort.

Ting-Yi ChenDavid A JacobJohn D CoppinChetan Jinadatha

Published in: Open forum infectious diseases (2024)

Our study revealed a low cumulative incidence of HBV reactivation after ibrutinib initiation among patients with previous anti-HBcAb positivity, indicating a moderate risk of HBV reactivation.

Keyphrases

hepatitis b virus
liver failure
chronic lymphocytic leukemia
risk factors
high intensity
quality improvement
single cell